Header Logo

Connection

Johnny Mahlangu to Isoantibodies

This is a "connection" page, showing publications Johnny Mahlangu has written about Isoantibodies.
Connection Strength

1,014
  1. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015 Nov; 13(11):1989-98.
    View in: PubMed
    Score: 0,509
  2. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
    View in: PubMed
    Score: 0,158
  3. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,133
  4. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29.
    View in: PubMed
    Score: 0,112
  5. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
    View in: PubMed
    Score: 0,042
  6. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,036
  7. Haemophilia management: time to get personal? Haemophilia. 2011 Sep; 17(5):721-8.
    View in: PubMed
    Score: 0,024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.